Chemaphor Announces Agreement With Allied Biotech Corporation

Chemaphor Inc. (TSX VENTURE:CFR) a biotechnology research and development company, is pleased to announce it has entered into a strategic relationship with the Allied Biotech Corporation of Taiwan. With this, Chemaphor has signed a Manufacturing Development Agreement with Allied Biotech for the development, manufacture and exclusive five year supply of Chemaphor’s OxBC compound. Dr. Paul [...]

Solarvest BioEnergy Inc. Announces Non-Brokered Private Placement

SOLARVEST BIOENERGY INC. (TSX VENTURE:SVS) (”Solarvest” or the “Company”), wishes to announce its non-brokered private placement, pursuant to which the investors will purchase from the Company up to 500,000 common shares at a price of $0.20 per share for gross proceeds of $100,000.
The private placement will be entirely subscribed by Related Parties of the Company [...]

Syngenta and Evogene to Collaborate on Soybean Nematode Resistance

Evogene Ltd. (TASE: EVGN) today announced a collaboration with Syngenta Biotechnology, Inc. focusing on identifying plant genes related to soybean nematode resistance. Under the agreement, Syngenta will receive exclusive licensing rights to candidate genes discovered by Evogene for use in soybean.
Soybean nematode is a soil parasite which attacks the roots of developing plants, and is [...]

Stem Cell Therapy International, Inc. Announces the Distribution of Histostem Products

Stem Cell Therapy International, Inc. (OTCBB: SCII), through its wholly owned subsidiary AmStem International, Inc., announced today that it has started the process to enable the Company to distribute Histostem and other stem cell related products.
In anticipation of the finalization of the merger between Stem Cell Therapy International, Inc. and Histostem, David Stark, SCTI President [...]

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

Biological drugs are the big winners in the market for autoimmune disorders. According to “Autoimmune Market Forecast to 2014,” the latest therapeutic market forecast from Cutting Edge Information, 11 of 14 drugs projected to reach blockbuster status are biologics. In fact, sales of biologics marketed for at least one autoimmune disorder topped $29 billion in [...]